LC
CSTL icon

Lindbrook Capital’s Castle Biosciences CSTL Stock Holding History

Lindbrook Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$3.58K Buy
179
+7
+4% +$173 ﹤0.01% 2087
2024
Q4 		$4.58K Sell
172
-16
-9% -$487 ﹤0.01% 2018
2024
Q3 		$5.36K Buy
188
+16
+9% +$407 ﹤0.01% 1983
2024
Q2 		$3.74K Hold
172
– – ﹤0.01% 2127
2024
Q1 		$3.81K Hold
172
– – ﹤0.01% 2021
2023
Q4 		$3.71K Buy
+172
New +$3.03K ﹤0.01% 2034
2023
Q2 		– Sell
-68
Closed -$1.54K – 2746
2023
Q1 		$1.54K Sell
68
-12
-15% -$293 ﹤0.01% 2345
2022
Q4 		$1.88K Sell
80
-61
-43% -$1.41K ﹤0.01% 2255
2022
Q3 		$4K Buy
141
+61
+76% +$1.71K ﹤0.01% 1742
2022
Q2 		$2K Buy
80
+64
+400% +$1.49K ﹤0.01% 1933
2022
Q1 		$1K Buy
+16
New +$661 ﹤0.01% 2198

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lindbrook Capital's CSTL Position: Q1 2025 in Review

Lindbrook Capital increased its Castle Biosciences (CSTL) stake by 4.1% in Q1 2025, buying an estimated $173 and bringing the position to 179 shares worth $3.58K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Lindbrook Capital first reported a position in CSTL in Q1 2022 and has held it in 11 quarters since. The position peaked at $5.36K in Q3 2024. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Lindbrook Capital held 179 shares of Castle Biosciences worth $3.58K as of Q1 2025.
  • Lindbrook Capital bought 7 Castle Biosciences shares in Q1 2025, an estimated $173.
  • Castle Biosciences made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2087 holding.
  • Lindbrook Capital first reported a position in Castle Biosciences in Q1 2022 and has held it in 11 quarters since.
  • Lindbrook Capital's Castle Biosciences position peaked at $5.36K in Q3 2024.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.